Quantcast

Latest Clinical research Stories

2014-09-25 16:26:37

SUNNYVALE, Calif. and SURESNES, France, Sept. 25, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) and Servier today announced that they have mutually and amicably ended their collaboration pertaining to the ex-U.S. development of Pharmacyclics' pan-HDAC inhibitor compounds involving abexinostat, thereby returning global development and commercialization rights to Pharmacyclics. "We thank Servier for their contribution in forwarding abexinostat to its current stage of...

2014-09-25 16:25:59

NEW YORK, Sept. 25, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. The investigation concerns whether Pacira and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On September 25, 2014, the...

2014-09-25 12:30:11

DUBLIN, Sept. 25, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 6th Edition" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 For six editions, this authoritative resource has defined the market opportunity for companies assisting in the beginning phase of the drug development process. 'Outsourcing in Drug Discovery' provides an in depth look into the...

2014-09-25 08:27:51

GLEN BURNIE, Md., Sept. 25, 2014 /PRNewswire/ -- CSSi (www.CSSiEnroll.com), the leader in patient recruitment solutions for the clinical research industry, is pleased to announce the recent appointment of two new hires, adding significant value and expertise to its offerings. CSSi has named Greg Fleming as Director of Business Development and Gemma Groppi as Senior Global Project Manager. Greg will be based on the West Coast working out of CSSi's San Francisco office while Gemma will...

2014-09-25 08:27:49

BUENA, N.J., Sept. 25, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, today announced it has acquired the regulatory rights and related documents and records for 18 drug products from AstraZeneca, 17 of which were marketed. The acquisition includes the regulatory rights and documents for 17 injectable products and 1 suppository product. All of these products had been previously approved by the US FDA as...

2014-09-25 08:27:36

BRIDGEWATER, N.J., Sept. 25, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, is pleased to announce that an Investigational New Drug application (IND) for Neutrolin(®) was submitted to the United States Food and Drug Administration (FDA) on Wednesday, September 24, 2014. The IND includes a pivotal Phase 3 protocol...

2014-09-24 23:02:33

The pressure to develop compliant and cost-effective drug stability testing programs is enormous. In this 6-hour virtual conference expert Charity Ogunsanya of Pharmabiodevice Consulting will provide in-depth training on protocol design, testing, storage, data management, trending and expiration dating extrapolations for approved products or new or existing products in the IND or NDA stage. Falls Church, VA (PRWEB) September 24, 2014 Designing and Sustaining Drug Stability Testing...

2014-09-24 20:23:16

REDWOOD CITY, Calif., Sept. 24, 2014 /PRNewswire/ -- Coherus BioSciences, Inc., a late-stage biologics platform company focused on the global biosimilar market, announced today the appointment of Mary Szela, Chief Executive Officer of Melinta Therapeutics, Inc., to its board of directors. "We are delighted to welcome Mary Szela to our team," said Denny Lanfear, President and Chief Executive Officer of Coherus. "Mary's experience in pharmaceutical sales and marketing will complement...

2014-09-24 16:26:24

SOUTH PLAINFIELD, N.J., Sept. 24, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Leerink Partners Rare Disease Roundtable on Wednesday, October 1st at 8:25 am ET at Le Parker Meridien in New York City. http://photos.prnewswire.com/prnvar/20010919/PTCLOGO The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at...

2014-09-24 16:26:22

SOUTH PLAINFIELD, N.J., Sept. 24, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on September 23, 2014 it approved non-statutory stock options to purchase an aggregate of 208,300 shares of its common stock to eighteen new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hires' employment compensation. http://photos.prnewswire.com/prnvar/20010919/PTCLOGO The inducement grants were approved by...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related